LEADER 00827nam0-22002771i-450- 001 990001664790403321 005 20050511095438.0 035 $a000166479 035 $aFED01000166479 035 $a(Aleph)000166479FED01 035 $a000166479 100 $a20030910d1899----km-y0itay50------ba 101 0 $aita 200 1 $a<>popolazione e l'agricoltura nel circondario di Ariano di Puglia$fFrancesco Festa 210 $aAvellino$cTip. Pergola$d1899 215 $a291 p.$d23 cm 610 0 $aSociologia rurale 676 $a307.72 700 1$aFesta,$bFrancesco$071899 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001664790403321 952 $a60 630.1 B 2$b19889$fFAGBC 959 $aFAGBC 996 $aPopolazione e l'agricoltura nel circondario di Ariano di Puglia$9373115 997 $aUNINA LEADER 05029nam 2201213z- 450 001 9910639987703321 005 20231214133552.0 010 $a3-0365-6133-1 035 $a(CKB)5470000001633477 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/95899 035 $a(EXLCZ)995470000001633477 100 $a20202301d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aIn Silico Strategies for Prospective Drug Repositionings 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (288 p.) 311 $a3-0365-6134-X 330 $aThe discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new anticancer drugs, new antivirals).Within this framework, drug repositioning?finding new pharmacodynamic properties for already approved drugs?becomes a worthy drug discovery strategy.Recent drug discovery techniques combine traditional tools with in silico strategies to identify previously unaccounted properties for drugs already in use. Indeed, big data exploration techniques capitalize on the ever-growing knowledge of drugs' structural and physicochemical properties, drug?target and drug?drug interactions, advances in human biochemistry, and the latest molecular and cellular biology discoveries.Following this new and exciting trend, this book is a collection of papers introducing innovative computational methods to identify potential candidates for drug repositioning. Thus, the papers in the Special Issue In Silico Strategies for Prospective Drug Repositionings introduce a wide array of in silico strategies such as complex network analysis, big data, machine learning, molecular docking, molecular dynamics simulation, and QSAR; these strategies target diverse diseases and medical conditions: COVID-19 and post-COVID-19 pulmonary fibrosis, non-small lung cancer, multiple sclerosis, toxoplasmosis, psychiatric disorders, or skin conditions. 606 $aMedicine$2bicssc 606 $aPharmaceutical industries$2bicssc 610 $aCOVID-19 610 $adrug repurposing 610 $atopological data analysis 610 $apersistent Betti function 610 $aSARS-CoV-2 610 $anetwork-based pharmacology 610 $acombination therapy 610 $anucleoside GS-441524 610 $afluoxetine 610 $asynergy 610 $aantidepressant 610 $anatural compounds 610 $aQSAR 610 $amolecular docking 610 $adrug repositioning 610 $aUK Biobank 610 $avaccine 610 $aLC-2/ad cell line 610 $adrug discovery 610 $adocking 610 $aMM-GBSA calculation 610 $amolecular dynamics 610 $acytotoxicity assay 610 $aGWAS 610 $amultiple sclerosis 610 $aoxidative stress 610 $arepurposing 610 $aADME-Tox 610 $abioinformatics 610 $acomplex network analysis 610 $amodularity clustering 610 $aATC code 610 $ahidradenitis suppurativa 610 $aacne inversa 610 $atranscriptome 610 $aproteome 610 $acomorbid disorder 610 $abiomarker 610 $asignaling pathway 610 $adruggable gene 610 $adrug-repositioning 610 $aMEK inhibitor 610 $aMM/GBSA 610 $aGlide docking 610 $aMD simulation 610 $aMM/PBSA 610 $asingle-cell RNA sequencing 610 $apulmonary fibrosis 610 $abiological networks 610 $ap38? MAPK 610 $aallosteric inhibitors 610 $ain silico screening 610 $acomputer-aided drug discovery 610 $anetwork analysis 610 $apsychiatric disorders 610 $amedications 610 $apsychiatry 610 $amental disorders 610 $atoxoplasmosis 610 $aToxoplasma gondii 610 $ain vitro screening 610 $adrug targets 610 $adrug-disease interaction 610 $atarget-disease interaction 610 $aDPP4 inhibitors 610 $alipid rafts 615 7$aMedicine 615 7$aPharmaceutical industries 700 $aUdrescu$b Lucre?ia$4edt$01279107 702 $aKurunczi$b Ludovic$4edt 702 $aBogdan$b Paul$4edt 702 $aUdrescu$b Mihai$4edt 702 $aUdrescu$b Lucre?ia$4oth 702 $aKurunczi$b Ludovic$4oth 702 $aBogdan$b Paul$4oth 702 $aUdrescu$b Mihai$4oth 906 $aBOOK 912 $a9910639987703321 996 $aIn Silico Strategies for Prospective Drug Repositionings$93014587 997 $aUNINA